CBLL
CeriBell, Inc. · Healthcare · Medical - Devices
动量输入(同类管理人):
持有人广度 +30.0% ·
股份流向 +8.4% ·
净新建仓位 +20.0%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 4.84M | — | $90.63M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (被动) | 1.52M | — | $28.46M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 3 | The Vanguard Group ✦ (被动) | 1.33M | — | $24.85M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Millennium Management ✦ | 470.15K | +24.7% | $8.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 447.94K | +55.4% | $8.39M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (被动) | 384.35K | +76.0% | $7.20M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 164.64K | 新增 | $3.08M | 0.0% | New | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 76.17K | 新增 | $1.43M | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | Point72 Asset Management ✦ | 66.43K | 新增 | $1.24M | 0.0% | New | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 44.14K | +41.4% | $826,798 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 12.47K | 新增 | $234,000 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Two Sigma Investments | $3.08M | 0.0% |
| Citadel Advisors | $1.43M | 0.0% |
| Point72 Asset Management | $1.24M | 0.0% |
| T. Rowe Price | $234,000 | 0.0% |
已清仓
| Soros Fund Management | $487,089 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 121 持有人, 29.58M 股份, $536.67M 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 4.89K 股 · $119,145
Officer, Director · 20.85K 股 · $521,775
Officer · 846 股 · $21,150
Officer · 7.50K 股 · $181,875
Officer · 1.75K 股 · $42,576
Officer · 4.89K 股 · $118,901
Officer · 652 股 · $16,300
Officer, Director · 39.54K 股 · $973,079
Officer · 859 股 · $20,573
Officer, Director · 6.07K 股 · $145,753
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论